Vericel Corporation (VCEL) News
Filter VCEL News Items
VCEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VCEL News Highlights
- VCEL's 30 day story count now stands at 2.
- Over the past 14 days, the trend for VCEL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NICK and STEP are the most mentioned tickers in articles about VCEL.
Latest VCEL News From Around the Web
Below are the latest news stories about VERICEL CORP that investors may wish to consider to help them evaluate VCEL as an investment opportunity.
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in AdultsFull commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid launch significantly expands the total addressable market for Vericel Burn Care CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S. commercial availability of |
Vericel to Present at the Morgan Stanley Global Healthcare ConferenceCAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http |
Vericel Corp. (VCEL) Rose on Positive Trend in the IndustryConestoga Capital Advisors, an asset management company, released its “Micro Cap Strategy” second-quarter 2023 investor letter. A copy of the same can be downloaded here. The Micro Cap Composite declined -1.53% net of fees in the second quarter, compared to the Russell Microcap Growth Index’s 6.35% return. Despite eight of the eleven sectors adding value to relative […] |
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue EstimatesVericel Corporation (VCEL) delivered earnings and revenue surprises of 15.38% and 7.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceRecord Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year 2023 Revenue Guidance Raised to $190-197 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and bu |
11 Best Healthcare Stocks Under $50In this article, we will be taking a look at the 11 best healthcare stocks under $50. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks Under $50. After the COVID-19 pandemic, many investors believed that the shining moment being enjoyed by healthcare and […] |
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel w |
Vericel (NASDAQ:VCEL) shareholders are still up 286% over 5 years despite pulling back 4.5% in the past weekWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... |
A Golden Ticket to Profiting From ‘Hidden’ Bull MarketsNo matter the macro environment, individualized bull markets happen all the time. |
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue EstimatesVericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |